Literature DB >> 19908925

Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

Tracy A Lieu1, G Thomas Ray, Ismael R Ortega-Sanchez, Ken Kleinman, Donna Rusinak, Lisa A Prosser.   

Abstract

BACKGROUND AND OBJECTIVES: A clear sense of what society is willing to pay for a QALY could enhance the usefulness of cost-effectiveness analysis as a field. Scant information exists on willingness to pay (WTP) for a QALY based on direct elicitation of preferences from community members or patients. We had the opportunity to evaluate WTP per QALY using data from a survey on temporary health outcomes related to herpes zoster. Our aims were to (i) describe how much community members are willing to pay to save a QALY based on scenarios describing temporary health states; (ii) evaluate how WTP per QALY varies based on experience with the disease being described and with demographic variables; and (iii) evaluate how the duration and intensity of pain in a scenario influences WTP per QALY.
METHODS: Community members drawn from a nationally representative survey research panel (n = 478) completed an Internet-based survey using time trade-off (TTO) and WTP questions to value a series of scenarios that described herpes zoster cases of varying pain intensity (on a scale of 0-10) and duration (30 days to 1 year). Patients with shingles (n = 354) or postherpetic neuralgia (PHN; n = 120) [defined as having symptoms for 90 days or more] from two large healthcare systems completed telephone interviews with similar questions. Mean and median WTP per QALY values were calculated by dividing the WTP amount by the discounted time traded for each scenario. Responses with a WTP value of more than zero and a TTO value of zero (which would have resulted in an undefined value) were excluded. TTO values were discounted by 3% per year. WTP per QALY means were calculated after trimming the top and bottom 2.5% of responses. Multivariate analyses were conducted using generalized linear mixed models that assumed a negative binomial distribution.
RESULTS: Among all respondents, the WTP per QALY ranged from a median of $US7000 to $US11,000 and a trimmed mean of $US26 000 to $US45,000 (year 2005 values), depending on the scenario described. WTP per QALY values varied significantly with respondent characteristics, as well as among respondents with similar characteristics. In multivariate analyses, the mean WTP per QALY was higher among respondents who were younger, male or had higher educational or income levels. After adjusting for these demographic variables, patients who had experienced shingles gave responses with the highest WTP per QALY values. Patients who had experienced PHN gave the lowest values, and community members gave values intermediate to the shingles and PHN groups. In multivariate models that evaluated the effects of pain and duration of the hypothetical zoster scenario, lower duration was associated with higher WTP per QALY. This effect appeared to be due to people increasing the amounts of time they would be willing to trade as duration increased, without proportional increases in the amounts of money they would be willing to pay.
CONCLUSIONS: Community members and patients gave mean WTP per QALY values that varied significantly based on age, sex, socioeconomic status, experience with shingles and duration of the health state evaluated. The variability in WTP per QALY suggests that it may be difficult to define a unitary threshold of dollars per QALY for policy making based on cost-effectiveness analyses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19908925     DOI: 10.2165/11314000-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  21 in total

1.  Willingness to pay for a QALY.

Authors:  Dorte Gyrd-Hansen
Journal:  Health Econ       Date:  2003-12       Impact factor: 3.046

2.  Importance of preference reversals in the valuation of health and healthcare.

Authors:  Adam Oliver; Corinna Sorenson
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2008-04       Impact factor: 2.217

3.  Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.

Authors:  Scott D Grosse
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2008-04       Impact factor: 2.217

Review 4.  Willingness to pay for a QALY: theoretical and methodological issues.

Authors:  Dorte Gyrd-Hansen
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Authors:  James M Pellissier; Marc Brisson; Myron J Levin
Journal:  Vaccine       Date:  2007-10-17       Impact factor: 3.641

6.  Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP?

Authors:  George Van Houtven; John Powers; Amber Jessup; Jui-Chen Yang
Journal:  Health Econ       Date:  2006-08       Impact factor: 3.046

7.  What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

Authors:  R Scott Braithwaite; David O Meltzer; Joseph T King; Douglas Leslie; Mark S Roberts
Journal:  Med Care       Date:  2008-04       Impact factor: 2.983

8.  Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Authors:  John Hornberger; Katherine Robertus
Journal:  Ann Intern Med       Date:  2006-09-05       Impact factor: 25.391

9.  Community and patient values for preventing herpes zoster.

Authors:  Tracy A Lieu; Ismael Ortega-Sanchez; G Thomas Ray; Donna Rusinak; W Katherine Yih; Peter W Choo; Irene Shui; Ken Kleinman; Rafael Harpaz; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

10.  Effect of assessment method on the discrepancy between judgments of health disorders people have and do not have: a web study.

Authors:  Jonathan Baron; David A Asch; Angela Fagerlin; Christopher Jepson; George Loewenstein; Jason Riis; Margaret G Stineman; Peter A Ubel
Journal:  Med Decis Making       Date:  2003 Sep-Oct       Impact factor: 2.583

View more
  15 in total

1.  Perspectives toward oral mucositis prevention from parents and health care professionals in pediatric cancer.

Authors:  Marie-Chantal Ethier; Dean A Regier; Deborah Tomlinson; Peter Judd; John Doyle; Adam Gassas; Ahmed Naqvi; Lillian Sung
Journal:  Support Care Cancer       Date:  2011-09-25       Impact factor: 3.603

Review 2.  Vaccination in the elderly: what can be recommended?

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Drugs Aging       Date:  2014-08       Impact factor: 3.923

3.  Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.

Authors:  Christian R C Kouakou; Thomas G Poder
Journal:  Eur J Health Econ       Date:  2021-08-21

4.  Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60.

Authors:  Casey R Tak; Jaewhan Kim; Karen Gunning; Catherine M Sherwin; Nancy A Nickman; Joseph E Biskupiak
Journal:  J Pharm Technol       Date:  2019-07-03

5.  Economic valuation of health care services in public health systems: a study about Willingness to Pay (WTP) for nursing consultations.

Authors:  Jesús Martín-Fernández; Ma Isabel del Cura-González; Gemma Rodríguez-Martínez; Gloria Ariza-Cardiel; Javier Zamora; Tomás Gómez-Gascón; Elena Polentinos-Castro; Francisco Javier Pérez-Rivas; Julia Domínguez-Bidagor; Milagros Beamud-Lagos; Ma Eugenia Tello-Bernabé; Juan Francisco Conde-López; Óscar Aguado-Arroyo; Ma Teresa Sanz-Bayona; Ana Isabel Gil-Lacruz
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

Review 6.  A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?

Authors:  Khachapon Nimdet; Nathorn Chaiyakunapruk; Kittaya Vichansavakul; Surachat Ngorsuraches
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

7.  Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences.

Authors:  Jesus Martín-Fernández; Elena Polentinos-Castro; Ma Isabel del Cura-González; Gloria Ariza-Cardiel; Victor Abraira; Ana Isabel Gil-LaCruz; Sonia García-Pérez
Journal:  BMC Health Serv Res       Date:  2014-07-03       Impact factor: 2.655

8.  Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

Authors:  Montarat Thavorncharoensap; Yot Teerawattananon; Sirin Natanant; Wantanee Kulpeng; Jomkwan Yothasamut; Pitsaphun Werayingyong
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-09

9.  Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries.

Authors:  Marc Evans; Kamlesh Khunti; Muhammad Mamdani; Claus B Galbo-Jørgensen; Jens Gundgaard; Mette Bøgelund; Stewart Harris
Journal:  Health Qual Life Outcomes       Date:  2013-06-03       Impact factor: 3.186

10.  Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective.

Authors:  Stewart B Harris; Kamlesh Khunti; Mona Landin-Olsson; Claus B Galbo-Jørgensen; Mette Bøgelund; Barrie Chubb; Jens Gundgaard; Marc Evans
Journal:  Patient Prefer Adherence       Date:  2013-09-16       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.